Immunotherapeutic Approaches to the Management of Head and Neck Cancer

Experts discuss the PD-1 checkpoint inhibitors nivolumab and pembrolizumab in the management of head and neck cancer, and how to choose between them.

Source: CancerNetwork - December 17, 2018 Category: Cancer & Oncology Authors: Xinyu Nan, MD, Kathryn A. Gold, MD, Ezra Cohen, MD Source Type: news